Vimarsana
Biggest News Aggregation in the World

Jerry Durso News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jerry Durso. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jerry Durso Today - Breaking & Trending Today

Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium - Vimarsana News

Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium

Shares of Intercept Pharmaceuticals Inc. were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy’s...

Alfasigma scoops up Intercept Pharmaceuticals in $794M buyout - Vimarsana News

Alfasigma scoops up Intercept Pharmaceuticals in $794M buyout

The acquisition will help boost Alfasigma’s gastroenterology and hepatology pipeline, all while giving it access to Intercept’s lead candidate Ocaliva.

Investors are raising shorts against these EV makers and a crypto play - Vimarsana News

Investors are raising shorts against these EV makers and a crypto play

Some on Wall Street are betting that these troubled stocks will keep falling.

Source: cnbc.com
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q2 2023 Earnings Call Transcript - Vimarsana News

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q2 2023 Earnings Call Transcript

Operator: Hello, and thank you for standing by. Welcome to Intercept Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

FDA Denies Approval of Obeticholic Acid for Pre-Cirrhotic Fibrosis Due to NASH - Vimarsana News

FDA Denies Approval of Obeticholic Acid for Pre-Cirrhotic Fibrosis Due to NASH

The FDA has issued a CRL to Intercept Pharmaceuticals regarding the NDA for obeticholic acid for pre-cirrhotic fibrosis due to NASH.

Source: empr.com